ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.77 USD
-0.35 (-11.22%)
Updated May 28, 2024 04:00 PM ET
After-Market: $2.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CDXC 2.77 -0.35(-11.22%)
Will CDXC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CDXC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDXC
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
CDXC: What are Zacks experts saying now?
Zacks Private Portfolio Services
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
Other News for CDXC
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
ChromaDex price target raised by 30c at Ladenburg, here's why
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates
Chromadex Poised for Continued Growth; Selvaraju Reiterates Buy Rating with $6 Target